Patients with severe lupus nephritis who have both diffuse proliferative (class IV) and membranous (class V) lesions on biopsy can be refractory to current monotherapy treatments. Bao et al.

Table 2. Results from randomized controlled trials comparing mycophenolate mofetil versus azathioprine for maintenance therapy in proliferative (class III–IV) lupus nephritis. AZA (120 mg/day ...

ALMS was a well-designed, randomized, controlled trial that included 370 patients with systemic lupus erythematosus (SLE) and class III, IV, or V nephritis. Like every recent major trial of new ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

The multi-centre, open-label trial aims to evaluate the safety and clinical activity of AlloNK plus monoclonal antibodies, rituximab or obinutuzumab in subjects with class III or class IV LN who ...

Originally approved in 2011 as an IV therapy for adults with SLE ... as the only biologic approved to treat SLE. Approval in lupus nephritis is expected to push the product above the $1 billion ...

Voclosporin is under clinical development by Aurinia Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Results from randomized controlled trials comparing mycophenolate mofetil versus azathioprine for maintenance therapy in proliferative (class III–IV) lupus nephritis. AZA (120 mg/day ...